Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

NCT03548935 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03548935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03548935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
June 4, 2018
Completion date
March 5, 2021
Enrollment
1,961 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

metabolism and nutrition disorder, overweight or obesity